Abbott Laboratories

NYSE:ABT

Sector

🏥 Health Care

Industries

🩺 Medical Instruments

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 233.80 B

Share Price

USD 134.38

Avg Daily Volume

7,103,166

Change (1 day)

0.53%

Change (1 year)

28.41%

Change (YTD)

18.80%

Abbott Laboratories Total Liabilities for the year ending December 31, 2024: USD 33.51 B

Abbott Laboratories Total Liabilities is USD 33.51 B for the year ending December 31, 2024, a -2.54% change year over year. Total liabilities are the total amount of a company's debts and other obligations.

Abbott Laboratories Total Liabilities for the year ending December 31, 2023 was USD 34.39 B, a -8.38% change year over year.
Abbott Laboratories Total Liabilities for the year ending December 31, 2022 was USD 37.53 B, a -4.18% change year over year.
Abbott Laboratories Total Liabilities for the year ending December 31, 2021 was USD 39.17 B, a -0.94% change year over year.
Abbott Laboratories Total Liabilities for the year ending December 31, 2020 was USD 39.55 B, a 8.09% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Liabilities	Shareholders' Equity	Cash and Short-Term Investments	Receivables

NYSE: ABT

Abbott Laboratories

CEO	Mr. Robert B. Ford
IPO Date	March 17, 1980
Location	United States
Headquarters	100 Abbott Park Road
Employees	114,000
Sector	🏥 Health Care
Industries Medical Instruments 🧬 Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.